Summarized by Masters of Longevity from Longevity Docs News.
Coverage of pharmaceutical market shifts and digital patient tools, previewing an article about drug sales dynamics and a company's expanded patient-support app.
Key Takeaways
- Tirzepatide (Mounjaro and Zepbound) generated significantly higher quarterly sales than Keytruda, indicating rapid adoption of GLP-1 therapies for metabolic conditions.
- Lilly expanded its Lilly Health app to support Mounjaro, Zepbound, and oral GLP-1 Foundayo, enabling patients to log doses, weight, and activity between clinical visits.
- Widespread patient use of Lilly's app means clinicians will increasingly see patient-generated monitoring data during consultations.
